Featured Slider

We congratulate the winners of the Investigator Awards to their presentation during the 2nd EAN Congress in Copenhagen 2016! The Prize consists of an Award certificate and free registration to the Amsterdam Congress. For the first time all winners’ presentations… Continue Reading

or April 2016 we have selected: Lublin F, Miller DH, Freedman MS, et al., on behalf of the INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomized, double-blind, placebo-controlled trial. Lancet Neurol, 27 Jan 2016; pii: S0140-6736(15)01314-8. doi: 10.1016/S0140-6736(15)01314-8. Primary progressive multiple sclerosis (PPMS) represents around 10-15% of the clinical forms of MS. Several characteristics differentiate PPMS from the relapse-onset MS, the classical more frequent form: older age at onset, equal prevalence between sexes, less inflammatory component at the MRI, and quicker progression of disability.

As in the previous years, EAN-RRFS delegate will join the EAN Spring School 2016 and the Regional Teaching courses (RTC) in order to spread information regarding postgraduate education in neurology and relevant opportunities for neurologists in training. This year, our representatives providing the updated information will be Panagiotis Zis (EAN Spring School 2016, May 12-15, 2016 Stare Splavy, Czech Republic), Orsolya Gyorfi (RTC, Kutasi, Georgia, Oct. 6-8, 2016), and Viktoria Papp (RTC, Yekaterinburg, Russia, Nov. 3-5, 2016).